LOGIN  |  REGISTER
Assertio
Terns Pharmaceuticals

Certara to Participate in Upcoming Investor Conferences

August 31, 2021 | Last Trade: US$11.02 0.05 0.46

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the following virtual investor conferences:

  • Morgan Stanley 19th Annual Global Healthcare Conference
    Date and Time: Tuesday, September 14 at 9:30 a.m. ET
    Speakers: William Feehery, chief executive officer, and Andrew Schemick, chief financial officer
  • Baird 2021 Global Healthcare Conference
    Date and Time: Wednesday, September 15 at 4:55 p.m. ET
    Speaker: Andrew Schemick, chief financial officer
  • Bank of America Securities 2021 Tech Solutions for Drug Discovery Conference
    Date and Time: Monday, September 20 at 8:00 a.m. ET
    Speakers: William Feehery, chief executive officer, and Andrew Schemick, chief financial officer

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Ariane Lovell
Finn Partners
This email address is being protected from spambots. You need JavaScript enabled to view it. 


Astria Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page